dpp 4 inhibitors vs glp 1 agonist Were DPP-4 the original GLP-1s? Use of DPP-4 inhibitors and
Description
Some employers have begun to include obesity medications as part of wellness initiatives, recognizing their potential to reduce long-term healthcare costs
The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead

Low-carbohydrate interventions for adolescent obesity: nutritional adequacy and guidance for clinical practice

ET COMPETING INTERESTS: None

Zhao L, Cheng Z, Lu Y, et al
